The assumption that ADHD stimulant misuse is spiraling upward among adults deserves scrutiny — and a major rapid review of 64 studies now provides the most comprehensive picture yet of who is actually misusing these medications, how often, and with what consequences. The findings meaningfully complicate the prevailing narrative.
Drawing on studies published between 2004 and 2024, including several large federally funded national surveys, the review found that past-year misuse rates among adults are declining rather than rising. In 2023, estimates ranged from 1.4% to 3.7% among young adults and approximately 1.9% across all adult ages. Misuse is disproportionately concentrated among younger, White, college-attending individuals in metropolitan areas. The predominant pattern is oral ingestion and infrequent use — not the high-intensity abuse often depicted. However, a distinct subgroup of high-frequency users presents a different risk profile: these individuals obtain stimulants from both physicians and illicit dealers and show markedly elevated rates of polysubstance use. Documented consequences include psychiatric hospitalizations, emergency department visits, and increased involvement with illicit substances. Critically, long-term evidence does not support a causal link between legitimate stimulant treatment during adolescence and subsequent substance use disorder.
This review arrives at a pivotal moment, as prescribing rates for adult ADHD medications have climbed sharply post-pandemic. The declining misuse trend challenges alarmist framings, but the high-frequency subgroup finding introduces a clinically meaningful nuance — concentration of harm in a smaller, identifiable population is precisely the kind of signal that should inform prescriber vigilance and monitoring protocols. Limitations are significant: many university-based studies suffered from low response rates and non-representative samples, reducing confidence in campus-specific estimates. The review is narrative rather than meta-analytic, meaning effect sizes cannot be pooled. Still, the convergence across high-quality national surveys lends the core trend credibility. For health-conscious adults navigating questions about stimulant use, this evidence suggests prescribed therapeutic use carries a different risk trajectory than non-prescribed misuse — a distinction the data now support more firmly.